Ascorbate plus buformin in aml: a metabolic targeted treatment

HIGHLIGHTS

  • who: Cristina Banella and colleagues from the Department of Health Sciences, Meyer Children`s University Hospital, Florence, Italy have published the article: Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment, in the Journal: (JOURNAL)
  • what: The authors characterized the metabolic background of different Leukemias` (AMLs) cells and described a heterogeneous and highly flexible energetic metabolism. The authors show that ascorbate inhibits glycolysis through interfering with HK1/2 and functions in hematopoietic cells. The authors compared the metabolic pathways underlying the different stages of differentiation of normal myeloid progenitors/precursors with that of primary blasts . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?